These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 8738588

  • 1. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
    Schenk JF, Glusa E, Radziwon P, Butti A, Markwardt F, Breddin HK.
    Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters.
    Glusa E, Barthel W, Schenk J, Radziwon P, Butti A, Markwardt F, Breddin KH.
    Haemostasis; 1998; 28(1):45-56. PubMed ID: 9885370
    [Abstract] [Full Text] [Related]

  • 6. Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers.
    Esslinger HU, Köhne S, Radziwon P, Walenga JM, Breddin HK.
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):79-88. PubMed ID: 12643328
    [Abstract] [Full Text] [Related]

  • 7. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
    Zoldhelyi P, Webster MW, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH.
    Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models.
    Diehl KH, Römisch J, Hein B, Jessel A, Ronneberger H, Pâques EP.
    Haemostasis; 1995 Nov; 25(4):182-92. PubMed ID: 7557657
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical pharmacology of recombinant hirudin.
    Markwardt F, Nowak G, Stürzebecher J.
    Haemostasis; 1991 Nov; 21 Suppl 1():133-6. PubMed ID: 1894188
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
    Zhao B, Zhang Y, Huang Y, Yu J, Li Y, Wang Q, Ma Y, Song HY, Yu M, Mo W.
    Thromb Haemost; 2017 Jan 05; 117(1):44-56. PubMed ID: 27904902
    [Abstract] [Full Text] [Related]

  • 20. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model.
    Klement P, Liao P, Hirsh J, Johnston M, Weitz JI.
    J Lab Clin Med; 1998 Sep 05; 132(3):181-5. PubMed ID: 9735923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.